Clinical trial

Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC

NCT06123754

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2023-11-17

PhasePHASE3

Conditions

Non-small Cell Lung Cancerverified · MONDO: non-small cell lung carcinoma

Interventions

Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injectionDRUG

placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injectionDRUG

Sponsors & collaborators

3D Medicines (Sichuan) Co., Ltd.lead sponsor

Mapped research locations

TianjinTianjin Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06123754 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.